Lijun International (01355.HK) Hotspot Analysis: Business Transformation to Synthetic Biology

Lijun International (01355.HK) has recently become a hotspot in Hong Kong stocks, with the core driver being its major transformation from traditional hotel business to the high-growth synthetic biology field [2]. On December 23, 2025, the company announced its renaming to “Biosysen Limited” and acquired a 37.5% indirect stake in Bei Sheng Bio, a synthetic biology infrastructure provider, for HK$22 million, officially entering the synthetic biology industry [2].

As one of the most dynamic high-growth fields globally, synthetic biology has applications across multiple industries including healthcare, agriculture, energy, and materials, and has received policy and funding support from the Chinese government [3]. In terms of price, as of December 31, 2025, the company’s share price was HK$0.125, with a year-to-date (YTD) gain of 31.32%, outperforming the Hang Seng Index’s 27.77% return over the same period [1]; the opening price on that day rose by 4.17% from the previous closing price, with an average trading volume of 609,573 shares [1]. In terms of market sentiment, investors are optimistic about its transformation prospects. As a small-cap stock with a market capitalization of approximately HK$149 million, it has attracted speculative investors seeking high-growth opportunities, but analyst coverage of this stock is limited [1].

1. Business Transformation Aligns with Industry Trends
   : The company’s shift from the mature hotel industry to synthetic biology leverages industry growth momentum and policy support, which is expected to bring new growth drivers.
2. Dual Impact of Small-Cap Characteristics
   : A smaller market capitalization is easily driven by speculative funds, leading to greater price volatility, but limited liquidity and analyst coverage also increase uncertainty.
3. Significant Challenges in Transformation Execution
   : The company lacks experience in the synthetic biology field, so there is considerable uncertainty about the success of the transformation; close attention should be paid to subsequent business integration and technology implementation.

• Transformation Execution Risk
  : The company has no experience in the synthetic biology industry, so the success of the transformation is uncertain.
• Financial Performance Risk
  : It recorded a net loss of HK$37.81 million in the past 12 months [1], with negative book value per share, making traditional valuation metrics difficult to apply.
• Small-Cap Volatility
  : Stock price volatility may be greater than that of large-cap stocks, requiring investors to bear higher price risks.

• Synthetic Biology Industry Growth
  : The industry has wide applications and rapid development, with large growth potential in both global and Chinese markets.
• Policy Support
  : The Chinese government’s support for the synthetic biology industry provides a favorable policy environment.
• Valuation Reconstruction Potential
  : If the transformation is successful, the company’s valuation is expected to be reconstructed from the traditional hotel industry to the high-growth technology/biology industry.

Lijun International (01355.HK) has become a Hong Kong stock hotspot due to its business transformation to the synthetic biology field, including renaming and acquiring a stake in Bei Sheng Bio. The stock has a significant YTD gain, outperforming the Hang Seng Index, but risks such as transformation execution, financial losses, and small-cap volatility need to be noted. Investors should combine their own risk preferences and understanding of the industry to pay attention to the company’s subsequent transformation progress.